Novartis already has Aimovig (erenumab) approved in Europe, along with Eli Lilly’s Emgality (galcanezumab), with both drugs available as monthly injections. With Ajovy, which is also from the ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...

The Phase III trial evaluated the safety and efficacy of monthly and quarterly subcutaneous injections of Ajovy compared to placebo in subjects with chronic migraine or episodic migraine.

Adverse drug reactions observed with Ajovy were mostly mild to moderate, short-lasting skin reactions around the injection area: pain, hardening, redness, itching and rash at the injection site.

Ajovy is used for the prevention of both episodic and chronic migraine. It is given by subcutaneous injection. It is self-administered once a month or in a higher dose every three months.

The most notable product launches include Ajovy (injection for treatment of migraine), Austedo (oral tablet for treatment of tardive dyskinesia and chorea associated with Huntington’s disease ...